Vorinostat Completed Phase 1 Trials for Childhood Central Nervous System Teratoma / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Medulloblastoma / Unspecified Childhood Solid Tumor, Protocol Specific / Recurrent Childhood Large Cell Lymphoma / Childhood Meningioma / Recurrent Childhood Central Nervous System Embryonal Tumor / Childhood Mixed Glioma / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Recurrent Childhood Visual Pathway and Hypothalamic Glioma / Childhood Craniopharyngioma / Childhood Burkitt Lymphoma / Childhood Choroid Plexus Tumor / Recurrent Childhood Small Noncleaved Cell Lymphoma / Childhood Central Nervous System Choriocarcinoma / Recurrent Childhood Cerebral Astrocytoma / Childhood Medulloepithelioma / Childhood Central Nervous System Germ Cell Tumor / Recurrent Childhood Subependymal Giant Cell Astrocytoma / Recurrent Childhood Pineoblastoma / Childhood Oligodendroglioma / Recurrent Childhood Malignant Germ Cell Tumor / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent/Refractory Childhood Hodgkin Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Visual Pathway Glioma / Recurrent Childhood Ependymoma / Childhood Central Nervous System Yolk Sac Tumor / Recurrent Childhood Brain Stem Glioma / Childhood Central Nervous System Mixed Germ Cell Tumor / Childhood Central Nervous System Germinoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00994500Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma